Citations

Mayo Clinic

Showing 10 of 108585 citations.

Glans Hypermobility Scale (GHS) Score: a Simple and Reliable Grading Scale for Glanular Hypermobility.
Köhler, Tobias , Ziegelmann, Matthew , Mian, Abrar , Dodge, Nicole, Mian, Raza, Suarez‐Sarmiento, Alfredo, Brennan, M., Perito, Paul , Mian, Abrar H , Helo, Sevann

No container title available | September 29, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3376563/v1 Get It

Abstract Glans hypermobility (GH) is a well-described clinical entity that can have significant implications for cosmesis and function, resulting in sexual dissatisfaction, penile pain, and early device erosion, with an estimated incidence of 0.04–10%. We developed a novel grading scale to assess GH severity intraoperatively during primary inflatable penile prosthesis (IPP) placement and describe a modified glanspexy technique to correct GH when encountered during IPP placement. A total of 530 patients underwent primary device implantation. Of these, 139 (26%) had hypermobility. Employing our new scaling system, grade 1, 2, and 3 GH was seen in 86 (16%), 29 (5.5%), and 24 (4.5%) cases, respectively. Increased implant size correlated with decreased likelihood of GH incidence. Each increase in implant size by 1 cm decreased the incidence of detecting GH by 11% (OR = 0.89; p = 0.015). 11 patients underwent primary GH repair using our described technique. At one-year follow-up, one patient required repeat glanspexy for recurrent bothersome GH and a second patient developed a suture granuloma at the glanspexy incision requiring unilateral cylinder explant. Our modified glanspexy technique can be used to correct GH in any direction and is a useful tool for the prosthetic surgeon’s armamentarium.
Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer
Kasi, Pashtoon Murtaza , Afable, Manuel, Herting, Cameron J. , Lukanowski, Mariusz, Jin, Zhaohui , Kasi, Pashtoon Murtaza , Jin, Zhaohui

The Oncologist | September 29, 2023 | Volume: 28 | Issue: 12 | Pages: 1034-1048

10.1093/oncolo/oyad262 | PMID 37774394 Get It

Abstract Colorectal cancer is the third most common cancer worldwide, and incidence is rising in younger individuals. Anti-EGFR antibodies, including cetuximab and panitumumab, have been incorporated into standard-of-care practice for patients with advanced disease. Herein, we review the molecular characteristics of these agents and the trials that lead to their approvals. Further, we discuss clinical implications of data regarding biomarkers that dictate treatment selection, different dosing strategies, and side effect management. Finally, we look towards the future and describe contexts in which these agents are currently being investigated clinically with a focus on combinations with MAPK-targeted therapies and immunotherapy. Overall, this review provides historical context, current clinical usage, and future directions for anti-EGFR antibodies in advanced colorectal cancer.
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Rivero, Jaydira Del , Perez, Kimberly , Kennedy, Erin B. , Mittra, Erik , Vijayvergia, Namrata , Arshad, Junaid , Basu, Sandip , Chauhan, Aman , Dasari, Arvind , Bellizzi, Andrew M. , Gangi, Alexandra , Grady, Erin , Ivanidze, Jana , Lewis, Mark A. , Mailman, Josh , Raj, Nitya , White, Sarah B. , Chan, Jennifer A. , Kunz, Pamela L. , Singh, Simron , Bergsland, Emily K. , Del Rivero, Jaydira , Dasari, Arvind N , Howe, James R , Raj, Nitya , Soares, Heloisa P , Soulen, Michael C , Kunz, Pamela L , Singh, Simron , Halfdanarson, Thorvardur R , Strosberg, Jonathan R , Bergsland, Emily K , Chauhan, Aman , Bellizzi, Andrew M , Vijayvergia, Namrata , Arshad, Junaid , Howe, James R. , Soares, Heloisa P. , Hálfdánarson, Þorvarður R. , Strosberg, Jonathan

Journal of Clinical Oncology | September 29, 2023 | Volume: 41 | Issue: 32 | Pages: 5049-5067

10.1200/jco.23.01529 | PMID 37774329 Get It

PURPOSE To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS Eight randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS Somatostatin analogs (SSAs) are recommended as first-line systemic therapy for most patients with G1-grade 2 (G2) metastatic well-differentiated GI-NETs. Observation is an option for patients with low-volume or slow-growing disease without symptoms. After progression on SSAs, peptide receptor radionuclide therapy (PRRT) is recommended as systematic therapy for patients with somatostatin receptor (SSTR)–positive tumors. Everolimus is an alternative second-line therapy, particularly in nonfunctioning NETs and patients with SSTR-negative tumors. SSAs are standard first-line therapy for SSTR-positive pancreatic (pan)NETs. Rarely, observation may be appropriate for asymptomatic patients until progression. Second-line systemic options for panNETs include PRRT (for SSTR-positive tumors), cytotoxic chemotherapy, everolimus, or sunitinib. For SSTR-negative tumors, first-line therapy options are chemotherapy, everolimus, or sunitinib. There are insufficient data to recommend particular sequencing of therapies. Patients with G1-G2 high-volume disease, relatively high Ki-67 index, and/or symptoms related to tumor growth may benefit from early cytotoxic chemotherapy. For G3 GEP-NETs, systemic options for G1-G2 may be considered, although cytotoxic chemotherapy is likely the most effective option for patients with tumor-related symptoms, and SSAs are relatively ineffective. Qualifying statements are provided to assist with treatment choice. Multidisciplinary team management is recommended, along with shared decision making with patients, incorporating their values and preferences, potential benefits and harms, and other characteristics and circumstances, such as comorbidities, performance status, geographic location, and access to care. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Lee, Yoo Jin , Li, Dalin , Debbas, Philip , Hampton, Melissa, Ebinger, Joseph E. , Chiorean, Michael , Lum, Donald , Damas, Oriana M. , Melmed, Gil , Group, CORALE-IBD Study, Banty, Andrea, Feldman, Edward J., Ha, Christina , Lee, Susie, Rabizadeh, Shervin , Stein, Theodore , Solomon, Theodore, Syal, Gaurav , Targan, Stephan R. , Vasiliauskas, Eric, Ziring, David , Bonthala, Niru, Botwin, Gregory S, Khanishian, Elizabeth, Pozdnyakova, Valeriya , Gu, Phillip , White, Shane , Zamudio, Cindy, Gonzalez, Daniel , Parry, Alyssa, Hanna, Mary , Chan, Justin, Ebinger, Joe , Wu, Min , Hoang, Amy, Wynter, Timothy , Sun, Nancy , Figueiredo, Jane C. , Merchant, Akil , Merin, Noah , Appel, Keren , Boland, Brigid S. , Charabaty, Aline , Cohen, Erica , Flynn, Ann D. , Valentine, John F. , Ehrlich, Adam C., Fudman, David , Horizon, Arash, Karayev, Dmitry, Kretzmann, Benjamin, Hou, Jason K. , Hwang, Caroline, Lazarev, Mark , Fausel, Rebecca, Reddy, Swapna , McConnell, Ryan , Mattar, Mark , Metwally, Mark, Ostrov, Arthur, Parekh, Nimisha, Raffals, Laura H., Sheibani, Sarah , Younes, Ziad , Braun, Jonathan , Melmed, Gil Y , Mujukian, Angela , Mengesha, Emebet , Cheng, Susan , McGovern, Dermot , Group, CORALE-IBD Study, Botwin, Gregory J., White, Shane, Joung, Sandy , Hoang, Amy, Reckamp, Karen L. , Kumar, Rashmi , Rubin, David T. , Siegel, Corey A , Wolf, Douglas C.

Inflammatory Bowel Diseases | September 29, 2023 | Volume: 30 | Issue: 8 | Pages: 1430-1434

10.1093/ibd/izad198 | PMID 37773982 Get It

RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults
Wen, Patrick Y. , Bent, Martin J. van den , Youssef, Gilbert , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Barboriak, Daniel P. , Groot, John de , Huang, Raymond Y. , Lassman, Andrew B. , Molinaro, Annette M. , Rahman, Rifaquat , Shankar, Lalitha , Macdonald, David R., Reardon, David A. , Vogelbaum, Michael A. , Chang, Susan M. , van den Bent, Martin J , Weller, Michael , Barboriak, Daniel P , de Groot, John , Huang, Raymond , Lassman, Andrew B , Mehta, Minesh P , Molinaro, Annette M. , Preusser, Matthias , Rahman, Rifaquat , Stupp, Roger , Villanueva-Meyer, Javier E. , Wick, Wolfgang , Reardon, David A , Vogelbaum, Michael A , Ellingson, Benjamin M , Cloughesy, Timothy F , Wen, Patrick Yung , Galanis, Evanthia , Gilbert, Mark R. , Mehta, Minesh P. , Preusser, Matthias , Stupp, Roger , Wick, Wolfgang

Journal of Clinical Oncology | September 29, 2023 | Volume: 41 | Issue: 33 | Pages: 5187-5199

10.1200/jco.23.01059 | PMID 37774317 Get It

PURPOSE The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. METHODS Informed by data from studies evaluating the different criteria, updates to the RANO criteria are proposed (RANO 2.0). RESULTS We recommend a standard set of criteria for both high- and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the postradiotherapy magnetic resonance imaging (MRI), rather than the postsurgical MRI, will be used as the baseline for comparison with subsequent scans. Since the incidence of pseudoprogression is high in the 12 weeks after radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, are required to define tumor progression. However, confirmation scans are not mandatory after this period nor for the evaluation of treatment for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (two-dimensional) but volumetric measurements are an option. For IDH wild-type glioblastoma, the nonenhancing disease will no longer be evaluated except when assessing response to antiangiogenic agents. In IDH-mutated tumors with a significant nonenhancing component, clinical trials may require evaluating both the enhancing and nonenhancing tumor components for response assessment. CONCLUSION The revised RANO 2.0 criteria refine response assessment in gliomas.
Quality measures for the care of pediatric patients with obstructive sleep apnea: 2023 update after measure maintenance
Lloyd, Robin M. , Crawford, T’Auna, Donald, Ryan, Gray, Diedra D., Junna, Mithri R. , Lewin, Daniel , Revana, Amee , Schutte-Rodin, Sharon, Healy, William J.

Journal of Clinical Sleep Medicine | September 29, 2023 | Volume: 20 | Issue: 1 | Pages: 127-134

10.5664/jcsm.10836 | PMID 37772707 Get It

ULK1 forms distinct oligomeric states and nanoscopic structures during autophagy initiation
Banerjee, Chiranjib , Mehra, Dushyant , Song, Daihyun , Mancebo, Angel , Park, Ji-Man , Kim, Do‐Hyung , Puchner, Elias M.

Science Advances | September 29, 2023 | Volume: 9 | Issue: 39 | Pages: No page available

10.1126/sciadv.adh4094 | PMID 37774021 Get It

Autophagy induction involves extensive molecular and membrane reorganization. Despite substantial progress, the mechanism underlying autophagy initiation remains poorly understood. Here, we used quantitative photoactivated localization microscopy with single-molecule sensitivity to analyze the nanoscopic distribution of endogenous ULK1, the kinase that triggers autophagy. Under amino acid starvation, ULK1 formed large clusters containing up to 161 molecules at the endoplasmic reticulum. Cross-correlation analysis revealed that ULK1 clusters engaging in autophagosome formation require 30 or more molecules. The ULK1 structures with more than the threshold number contained varying levels of Atg13, Atg14, Atg16, LC3B, GEC1, and WIPI2. We found that ULK1 activity is dispensable for the initial clustering of ULK1, but necessary for the subsequent expansion of the clusters, which involves interaction with Atg14, Atg16, and LC3B and relies on Vps34 activity. This quantitative analysis at the single-molecule level has provided unprecedented insights into the behavior of ULK1 during autophagy initiation.
Microvascular Free Flap Outcomes in Maxillectomy Defects from Invasive Fungal Sinusitis
Rao, Shilpa M., Knott, P. Daniel , Sweeny, Larissa , Domack, Aaron , Tang, Alice , Patel, Rusha , Pittman, Amy , Gardner, James Reed , Moreno, Mauricio A. , Sunde, Jumin , Cave, Taylor B., Knight, Nicolaus D., Greene, Ben, Pipkorn, Patrik , Joshi, Arjun S. , Ji, Keven Seung Yong , Yang, Sara , Wax, Mark K. , Thomas, Carissa M. , Gardner, J Reed , Chang, Brent A , Wax, Mark K , Thomas, Carissa M , Sweeny, Larissa , Rao, Shilpa M., Thakkar, Punam , Chang, Brent A.

The Laryngoscope | September 29, 2023 | Volume: 134 | Issue: 4 | Pages: 1642-1647

10.1002/lary.31081 | PMID 37772913 Get It

ObjectivesMicrovascular free tissue transfer is routinely used for reconstructing midface defects in patients with malignancy, however, studies regarding reconstructive outcomes in invasive fungal sinusitis (IFS) are lacking. We aim to describe outcomes of free flap reconstruction for IFS defects, determine the optimal time to perform reconstruction, and if anti‐fungal medications or other risk factors of an immunocompromised patient population affect reconstructive outcomes.MethodsRetrospective review of reconstruction for IFS (2010–2022). Age, BMI, hemoglobin A1c, number of surgical debridements, and interval from the last debridement to reconstruction were compared between patients with delayed wound healing versus those without. Predictor variables for delayed wound healing and the effect of time on free flap reconstruction were analyzed.ResultsTwenty‐seven patients underwent free flap reconstruction for IFS. Three patients were immunocompromised from leukemia and 21 had diabetes mellitus (DM). Patients underwent an average of four surgical debridements for treatment of IFS. The interval from the last IFS debridement to flap reconstruction was 5.58 months (±5.5). Seven flaps (25.9%) had delayed wound healing. A shorter interval of less than 2 months between the last debridement for IFS and reconstructive free flap procedure was associated with delayed wound healing (Fisher Exact Test p = 0.0062). Other factors including DM, BMI, HgA1c, and bone reconstruction were not associated with delayed wound healing.ConclusionPatients with maxillectomy defects from IFS can undergo microvascular‐free flap reconstruction with good outcomes while on anti‐fungal medication. Early reconstruction in the first 2 months after the last IFS debridement is associated with delayed wound healing.Level of Evidence4 Laryngoscope, 134:1642–1647, 2024
Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM
Petronek, Michael S. , Monga, Varun , Bodeker, Kellie L. , Kwofie, Michael , Lee, Chu‐Yu , Stolwijk, Jeffrey M. , Zaher, Amira , Wagner, Brett A. , Smith, Mark C. , Vollstedt, Sandy , Brown, Heather , Chandler, Meghan L. , Lorack, Amanda C. , Wulfekuhle, Jared S. , Flynn, Ryan T. , Jones, Karra A. , Magnotta, Vincent A. , Mapuskar, Kranti A , Stolwijk, Jeffrey M , Zaher, Amira , Wagner, Brett A , Smith, Mark C , Vollstedt, Sandy , Brown, Heather , Chandler, Meghan L , Lorack, Amanda C , Wulfekuhle, Jared S , Sarkaria, Jann N , Flynn, Ryan T , Greenlee, Jeremy D W , Howard, Matthew A , Smith, Brian J , Jones, Karra A , Buettner, Garry R , Cullen, Joseph J , St-Aubin, Joel , Buatti, John M , Magnotta, Vincent A , Spitz, Douglas R , Allen, Bryan G , Monga, Varun , Mapuskar, Kranti A. , Sarkaria, Jann N. , Greenlee, Jeremy D.W. , Howard, Matthew A. , Buettner, Garry R. , Buatti, John M. , Spitz, Douglas R.

Clinical Cancer Research | September 29, 2023 | Volume: 30 | Issue: 2 | Pages: 283-293

10.1158/1078-0432.ccr-22-3952 | PMID 37773633 Get It

Abstract Purpose: Pharmacologic ascorbate (P-AscH−) is hypothesized to be an iron (Fe)-dependent tumor-specific adjuvant to chemoradiation in treating glioblastoma (GBM). This study determined the efficacy of combining P-AscH− with radiation and temozolomide in a phase II clinical trial while simultaneously investigating a mechanism-based, noninvasive biomarker in T2* mapping to predict GBM response to P-AscH− in humans. Patients and Methods: The single-arm phase II clinical trial (NCT02344355) enrolled 55 subjects, with analysis performed 12 months following the completion of treatment. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method and compared across patient subgroups with log-rank tests. Forty-nine of 55 subjects were evaluated using T2*-based MRI to assess its utility as an Fe-dependent biomarker. Results: Median OS was estimated to be 19.6 months [90% confidence interval (CI), 15.7–26.5 months], a statistically significant increase compared with historic control patients (14.6 months). Subjects with initial T2* relaxation < 50 ms were associated with a significant increase in PFS compared with T2*-high subjects (11.2 months vs. 5.7 months, P < 0.05) and a trend toward increased OS (26.5 months vs. 17.5 months). These results were validated in preclinical in vitro and in vivo model systems. Conclusions: P-AscH− combined with temozolomide and radiotherapy has the potential to significantly enhance GBM survival. T2*-based MRI assessment of tumor iron content is a prognostic biomarker for GBM clinical outcomes. See related commentary by Nabavizadeh and Bagley, p. 255
Treatment options for necrobiosis lipoidica: a systematic review
Nihal, Aman , Caplan, Avrom S. , Rosenbach, Misha , Damsky, William , Mangold, Aaron R. , Shields, Bridget E. , Mangold, A R

International Journal of Dermatology | September 29, 2023 | Volume: 62 | Issue: 12 | Pages: 1529-1537

10.1111/ijd.16856 | PMID 37772666 Get It

AbstractBackgroundNecrobiosis lipoidica (NL) is a rare, idiopathic, and recalcitrant disease of collagen degeneration for which treatment options have been poorly studied. Due to its recurring nature, risk for ulceration, and high morbidity, there is a need to understand existing treatment modalities to better inform clinical care.ObjectiveThis review aims to describe the therapeutic modalities reported in the literature for the treatment of NL.MethodsA literature search of treatments was performed by searching for publications between January 2016 and May 2022 on PubMed and Scopus. Given the limited high‐quality evidence, case reports and series were included. Only publications presenting information on both attempted treatments and outcomes were included.ResultsA total of 60 novel articles were identified (54 case reports, two case series, and four retrospective cohort studies). These studies cumulatively reported on 274 patients and covered treatments including phototherapy, topical corticosteroids, topical calcineurin inhibitors, biologics, immunosuppressants, JAK inhibitors, combination therapies, and several others. The greatest amount of evidence was found for photodynamic therapy (improvement in 72 of 80 patients), UVA‐based phototherapy (12 of 33), topical corticosteroids (21 of 46), compression therapy (15 of 20), and topical calcineurin inhibitors (11 of 17). Several newer treatments were also described, including ustekinumab and JAK inhibitors.ConclusionsThis systematic review provides a comprehensive summary of recently published treatments for NL. As the existing data comes predominantly from case reports and series, statistical conclusions are not assessed. A greater number of randomized controlled trials with standardized endpoints are necessary to compare treatment efficacy.